Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 68Breast Neoplasms 58Carcinoma, Non-Small-Cell Lung 36Triple Negative Breast Neoplasms 28Squamous Cell Carcinoma of Head and Neck 15Neoplasms 11Head and Neck Neoplasms 11Lung Neoplasms 10Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 7Stomach Neoplasms 6Melanoma 6Adenocarcinoma 6Esophageal Neoplasms 5Cholangiocarcinoma 5Advanced Pancreatic Cancer 5Inflammatory Breast Neoplasms 4Gallbladder Neoplasms 4Fallopian Tube Neoplasms 4Carcinoma 4Small Cell Lung Carcinoma 3Recurrence 3Pathologic Complete Response 3Ovarian Neoplasms 3Neoplasms by Site 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Squamous Cell 3Uveal Melanoma 2Uterine Cervical Neoplasms 2

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × 130-nm albumin-bound paclitaxel × Clear all
NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

SCRI Development Innovations, LLC

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡